Descovy — Total revenues
Gilead Sciences Descovy — Total revenues decreased by 1.3% to $807.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 37.7%, from $586.00M to $807.00M. Over 3 years (FY 2022 to FY 2025), Descovy — Total revenues shows an upward trend with a 13.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand, successful patient retention, or effective pricing strategies for the therapy. A decrease may signal increased competition from generics, shifts in clinical treatment guidelines, or the natural maturation of the product lifecycle.
Detailed definition
This metric represents the total gross revenue generated from the sales of a specific HIV treatment product line. It ref...
Peer comparison
Comparable to product-specific revenue reporting for branded pharmaceutical therapies in the infectious disease or oncology sectors at peer biopharmaceutical companies.
gild_segment_descovy_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $468.00M | $468.00M | $468.00M | $468.00M | $496.25M | $496.25M | $496.25M | $496.25M | $426.00M | $485.00M | $586.00M | $616.00M | $586.00M | $653.00M | $701.00M | $818.00M | $807.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +6.0% | +0.0% | +0.0% | +0.0% | -14.2% | +13.8% | +20.8% | +5.1% | -4.9% | +11.4% | +7.4% | +16.7% | -1.3% |
| YoY Change | — | — | — | — | +6.0% | +6.0% | +6.0% | +6.0% | -14.2% | -2.3% | +18.1% | +24.1% | +37.6% | +34.6% | +19.6% | +32.8% | +37.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's descovy — total revenues?
- Gilead Sciences (GILD) reported descovy — total revenues of $807.00M in Q1 2026.
- How has Gilead Sciences's descovy — total revenues changed year-over-year?
- Gilead Sciences's descovy — total revenues increased by 37.7% year-over-year, from $586.00M to $807.00M.
- What is the long-term trend for Gilead Sciences's descovy — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's descovy — total revenues has grown at a 13.8% compound annual growth rate (CAGR), from $1.87B to $2.76B.
- What does descovy — total revenues mean?
- The total sales revenue generated by a specific HIV medication product line.